Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers.

[1]  Yung-chi Cheng,et al.  Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model , 2000, Antimicrobial Agents and Chemotherapy.

[2]  Y. Cheng,et al.  Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. , 1999, Biochemical pharmacology.

[3]  Y. Cheng,et al.  Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. , 1999, Journal of medicinal chemistry.

[4]  Z. Jiang,et al.  Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria* , 1999, The Journal of Biological Chemistry.

[5]  Shwu-Huey Liu,et al.  Anti-Hepatitis B Virus Activity and Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine , 1998, Antimicrobial Agents and Chemotherapy.

[6]  M. Kukhanova,et al.  Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus β-d(+) Nucleoside Analogs In Vitro , 1998, Antimicrobial Agents and Chemotherapy.

[7]  Y. Cheng,et al.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.

[8]  M. Kukhanova,et al.  Interaction of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design. , 1998, Molecular pharmacology.

[9]  M. Kukhanova,et al.  Unique inhibitory effect of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil 5'-triphosphate on Epstein-Barr virus and human DNA polymerases. , 1998, Biochemical pharmacology.

[10]  C. K. Chu,et al.  Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-. beta.-L-arabinofuranosyl)purine Nucleosides. , 1997 .

[11]  M. Newton,et al.  Synthesis and Anti-Hepatitis B Virus Activity of 9-(2-Deoxy-2-fluoro-β-l-arabinofuranosyl)purine Nucleosides , 1997 .

[12]  E. Gullen,et al.  Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro , 1996 .

[13]  M. Kukhanova,et al.  Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 1996, Biochemical pharmacology.

[14]  Y. L. Zhu,et al.  Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil , 1996, Antimicrobial agents and chemotherapy.

[15]  Y. Cheng,et al.  Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. , 1995, Progress in liver diseases.

[16]  R. Schinazi,et al.  Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. , 1992, The Journal of biological chemistry.

[17]  R. Schinazi,et al.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. H. Chen,et al.  Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. , 1991, Molecular pharmacology.

[19]  C. H. Chen,et al.  Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.